Commercial-stage specialty pharmaceutical company.
Acquired by Zydus in 2017
Acquired by Zydus in 2017
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 12.08.2026 | Oral Pill for Rare Lung Disease Blocks 90% of Damaging Enzyme in Phase 2, Lands $475M Deal | By Benjamin Eddie Published: Aug 12 2026, 3:29 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 12.07.2024 | Sciensus partners with Sentynl Therapeutics to become the exclusive distribution partner of NULIBRY® in Europe | Sciensus, a life sciences business, to become the exclusive distribution partner for Sentynl’s drug NULIBRY in Europe. We are pleased to be partnering with Sentynl to provide programmes which will offer patients in Europe access to potentia... |
| 13.10.2021 | Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition | NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licensing partner Senty... |